Adenoid (Acantholytic) Squamous Cell Carcinoma of Mandibular Gingiva

Oral Acantholytic Squamous Cell Carcinoma: A Rare Case of Mandibular Alveolar Ulceration

Acantholytic squamous cell carcinoma (ASCC) is an atypical form of squamous cell carcinoma (SCC). Although it is well known that ASCC typically appears in sun-exposed regions of the face and neck, oral cavity cases are incredibly rare. In this case report, we present a rare case of a 50-year-old male who developed an ulcer on his right mandibular alveolus, diagnosed with ASCC post-biopsy. On histopathological analysis, acantholytic cells with a pseudo-glandular appearance were observed. Subsequently, the tumor was resected by modified radical neck dissection with a split-thickness graft. The patient responded well to surgery and had no complications post-surgery.

Acantholytic oral squamous cell carcinoma with clear cell change - a rare amalgamated variant

Background

Acantholytic squamous cell carcinoma (ASCC) is an uncommon histological variation of oral squamous cell carcinoma (OSCC), accounting for fewer than 4% of all occurrences. The tumor shows a slight masculine predisposition, with the lower lip being the most commonly affected location. ASCC is reported to have a diverse biologic behavior, which explains its ability to metastasize to distant places and, thus, its poor prognosis. Similarly, clear cell change in OSCC is a rare occurrence with an unknown etiology that suggests its aggressive nature.

Method and Results

Histopathology reveals central acantholytic cells with numerous duct-like features. The presence of distinct cytological atypia contributes to the diagnosis of SCC. Special stains and IHC aid in distinguishing tumor from other histopathologically similar entities.

Conclusion

The case of a 29-year-old male presented here with an updated literature review highlights the need for histological study of the unique and seldom seen oral ASCC with clear cell change, which can be ignored because of similarities with other entities. Because recurrence rates are so high for ASCC, amalgamated clear cell change makes it critical for proper treatment initiation with a definite diagnosis. To the best of our knowledge, this is the first documented occurrence. Our experience with the present case suspected a more aggressive behavior due to a high Ki-67 index, anticipating a poorer prognosis in the oral cavity considering the patient's young age.

Neoadjuvant therapy for HER2-positive acantholytic squamous cell breast carcinoma: a case report

HER2-positive acantholytic squamous cell carcinoma (ASCC) of the breast is exceptionally rare, and its clinicopathologic features are poorly understood. The impact of neoadjuvant therapy on HER2-positive breast ASCC is unclear. Here we report on a 58-year-old woman who was diagnosed with HER2-positive ASCC of the right breast, who underwent neoadjuvant treatment with albumin-paclitaxel, carboplatin, and trastuzumab, and surgery. Neoadjuvant therapy was effective, with no recurrence or metastasis after 1.5 years of postoperative follow-up.